Particula | $5,500,000 | (May 1, 2025)
Stimuler | $3,750,000 | (May 1, 2025)
SpriveApp | $7,300,000 | (May 1, 2025)
Certified by Founder
Lodge
HI-Bio
start up
United States
- South San Francisco, California
- 05/01/2024
- Series B
- $95,000,000
Human Immunology Biosciences (HI-Bio) is leading clinical immunology into its next chapter with therapies that target cellular drivers of disease. HI-Bio uses a precision medicine approach to deliver therapies for patients with the auto-immune, allergic and inflammatory diseases that can together be referred to as immune-mediated diseases (IMDs).
- Industry Biotechnology Research
- Website https://hibio.com/
- LinkedIn https://www.linkedin.com/company/hibio/about/
Manifest | $15,000,000 | (May 1, 2025)
Spark Biomedical Inc | $15,000,000 | (May 1, 2025)
Queens Carbon | $10,000,000 | (May 1, 2025)
Noma Therapy | $4,250,000 | (May 1, 2025)
Persona | $200,000,000 | (May 1, 2025)
Nuvo | $45,000,000 | (May 1, 2025)
Pallie | $2,000,000 | (May 1, 2025)
Faye(US) | $2,500,000 | (May 1, 2025)
Structify | $4,100,000 | (May 1, 2025)